Insmed reported further durability data for its once-daily pulmonary arterial hypertension therapy TPIP via an open-label extension of a Phase IIb trial. The treated-arm benefits were maintained over 24 months, and patients who switched from placebo to TPIP after initial controls saw similar improvements after 12 months. Insmed positioned the results around post-dose assessment timing and compared dosing cadence against other inhaled treprostinil formulations in the space, reinforcing the company’s differentiation on regimen simplicity and long-term maintenance.